Currently Viewing:
Newsroom
Currently Reading
Outcomes-Based Contract Between Highmark, AstraZeneca Reveals Positive Results for Patients With Asthma and COPD
November 01, 2019 – Matthew Gavidia
Researchers Explore Costs of Switching to Environmentally Friendly Inhalers for Asthma
October 31, 2019 – Christina Mattina
This Week in Managed Care: October 25, 2019
October 25, 2019
FDA Approves Novel Triple Combination Therapy for Cystic Fibrosis
October 21, 2019 – Matthew Gavidia
Water Treatment Strategies Vary in Effectiveness Against Bacterial Species Causing Respiratory Infections
October 17, 2019 – Christina Mattina
Immunological Characteristics as Potential Treatment Targets in Refractory CRS With Nasal Polyps
October 09, 2019 – Christina Mattina
Research Identifies Asthma Endotypes Suggesting Different Treatment Strategies
October 09, 2019 – Christina Mattina
Digital Inhaler Interest Growing Among Patients With Severe Forms of COPD or Asthma
October 03, 2019 – Matthew Gavidia
Three-in-One Inhaler Found to Improve Lung Function, Reduce Asthma Attacks in 2 Phase 3 Trials
October 02, 2019 – Matthew Gavidia

Outcomes-Based Contract Between Highmark, AstraZeneca Reveals Positive Results for Patients With Asthma and COPD

Matthew Gavidia
Highmark announced this week that its outcomes-based contract with AstraZeneca for the respiratory combination medication of budesonide/formoterol (Symbicort) revealed positive results in improving outcomes for those with asthma and chronic obstructive pulmonary disease (COPD).
Highmark announced this week that its outcomes-based contract with AstraZeneca for the respiratory combination medication of budesonide/formoterol (Symbicort) revealed positive results in improving outcomes for those with asthma and chronic obstructive pulmonary disease (COPD).

The combination medication, approved for the treatment of asthma and COPD, assists in decreasing inflammation and opening the airways in patients’ lungs. As a way to ensure that members have access to the most clinically effective, cost-efficient medications available, Highmark announced that it had created an outcomes-based contact with AstraZeneca for the medication in April 2018. Highmark and AstraZeneca’s contract for budesonide/formoterol served as 1 of the first outcomes-based agreements involving asthma and COPD.

Outcomes-based contracts set drug companies accountable for the clinical effectiveness of medications and the per-member per-month medical and pharmacy costs for members who use the drug compared with the costs for members who use other drugs for treating their condition. For the contract, Highmark analyzed specific pharmacy and medical criteria to evaluate if asthma- or COPD-related symptoms for their patients using the combination medication were aligned with clinical trial results presented by AstraZeneca.

In relating AstraZeneca’s claimed findings, Highmark set the contract target for patient-experienced exacerbation events at 50% or less in the commercial population. Highmark had more than 30,000 claims for budesonide/formoterol in 2018 from its national health insurance markets and its core health insurance markets in Pennsylvania, West Virginia, and Delaware. Under the contract design, patients had to have a primary diagnosis of COPD or asthma with additional age restrictions for each of the cohorts.

Highmark revealed that in the findings, positive outcomes were exhibited as members met the target goal of experiencing less than a 50% rate of exacerbations.

Sarah Marchè, PharmD, senior vice president of pharmacy services for Highmark, stressed the value of assessing medications to ensure and display efficacy. “Outcomes-based agreements like this show the value of medicines like SYMBICORT to both patients and the health system in reducing exacerbations, hospitalizations, and inpatient visits,” Marchè said.

The insurer additionally found that the number of patients taking budesonide/formoterol who saw a worsening of symptoms requiring them to visit a healthcare provider or hospital was substantially lower than what they expected.

“As Highmark furthers its leadership in value-based strategies, results like these are proof that a shared commitment to identifying the right medicine and approach in a priority therapy area can improve patient outcomes,” Marchè said.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up